Drs. Owens and de Feria review emerging data on epicardial adipose tissue and MRI-based markers to refine hypertrophic cardiomyopathy risk assessment. They highlight integrating imaging and biomarkers, including NT‑proBNP, to predict heart failure and arrhythmic outcomes.

Drs. Kittleson and Ghafourian discuss how to accurately diagnose ATTR-CM, emphasizing that the first step must always be a complete monoclonal protein screen to exclude AL amyloidosis before interpreting a PYP scan. They highlight common pitfalls with PYP imaging; the supportive (but not definitive) role of cardiac MRI; the need for routine TTR genotyping after diagnosis; and the importance of recognizing noncardiac clues to identify patients early enough to benefit from disease‑modifying therapies.

Drs. Chase and Griffiths discuss how to choose biologic therapies for allergic asthma using a personalized approach based on biomarkers, asthma severity, comorbid type 2 diseases, and practical factors (eg, dosing and access). They highlight the importance of reducing steroid use, educating patients about biologics, and continually reassessing treatment to improve control and quality of life.

This episode highlights back-to-school vaccination priorities amid updated pediatric guidance and ongoing measles activity, new evidence linking adolescent sleep disruption and school transitions with anxiety and declining well-being, and the importance of ensuring schools are prepared to manage asthma and other chronic conditions.

This episode highlights FDA approval of the first-in-class RAS inhibitor daraxonrasib for metastatic pancreatic adenocarcinoma, concerning gaps in cervical cancer screening and HPV vaccination among younger women, and new evidence defining which patients may benefit most from coronary artery calcium scoring alongside the PREVENT cardiovascular risk calculator.

Drs. Garg and Mehta discuss how advances in vitrectomy technology, imaging, and heads-up display systems are changing surgical decision-making and improving outcomes for diabetic retinopathy, tractional retinal detachments, and visually significant floaters. They emphasize earlier surgical intervention in select diabetic cases, careful patient selection and counseling, and the importance of ergonomics and visualization tools for both surgeon longevity and teaching.

Drs. Ungar and Cices discuss how to interpret long-term safety data for systemic therapies in moderate-to-severe atopic dermatitis, emphasizing the importance of balancing safety signals against the harms of uncontrolled chronic inflammation. They highlight real-world evidence—especially for JAK inhibitors and biologics like dupilumab—as increasingly reassuring, while stressing individualized risk assessment based on patient age, comorbidities, and background cardiovascular risk.

Drs. Berger and Denny review recent stroke conference data on Factor XIa inhibitors and evolving strategies for secondary stroke prevention. They highlight image-guided extended‑window tenecteplase to broaden reperfusion eligibility.

Drs. Montesi and Martinez discuss how the emerging PRIME-PPF clinical cohort study and biomarker research will sharpen definitions of disease progression and transform treatment decisions in non-IPF ILD. They highlight the potential for clinicians to use integrated data (eg, symptoms, physiology, imaging, and circulating proteomic signatures) to initiate antifibrotic and combination therapies earlier, tailoring them to individual patients while also balancing side effects and standard immunomodulatory care.

This episode highlights three clinically relevant developments: positive phase 3 results for individualized mRNA neoantigen therapy plus pembrolizumab after melanoma surgery, emerging MRI and AI approaches that may identify Alzheimer’s-related brain changes years earlier, and substantial LDL-C treatment gaps under the 2026 ACC/AHA dyslipidemia guideline. Together, the findings underscore advances in precision oncology, early neurodegenerative risk detection, and cardiovascular prevention.